All updated as on -
During the projection period (2024-2031), the global induced pluripotent stem cell production market is expected to expand from an initial valuation of 1.29 billion USD in 2023 to a total value of 2.81 billion USD by 2031, with a compound annual growth rate (CAGR) of 12.5%.
With the advent of new regenerative medical drugs and mobile treatments, the worldwide market for induced pluripotent stem cell (iPSC) production has seen tremendous growth and innovation. An significant opportunity for the creation of individualized treatment plans and disease models exists in IPSCs, which can be reprogrammed from human cells into a pluripotent state.
An increasing body of knowledge on the potential applications of iPSCs in fields ranging from drug development to the treatment of various medical conditions is driving this market. Green induced pluripotent stem cell (iPSC) manufacturing that is both cost-effective and scalable is a hot topic among researchers and biotech companies. Innovations in this field are being propelled by partnerships between educational institutions, businesses, and healthcare facilities.
Furthermore, the need for standardized procedures and safety protocols is highlighted by the fact that strict regulatory frameworks and ethical concerns continue to play a significant role in defining the iPSC manufacturing landscape. With the ever-changing healthcare landscape on a global scale, the iPSC manufacturing market is set to continue growing, opening up new possibilities for medical discoveries and advancements in science.
The COVID-19 pandemic prompted a surge in research efforts, and within those efforts, iPSC-based studies saw a significant uptick. Researchers' incessant pursuit of better ways to control the spread of the SARS-CoV-2 virus has increased interest in induced pluripotent stem cells (iPSCs). Furthermore, the pathophysiology of human viral infection can be studied using generated pluripotent stem cells since these cells have the ability to differentiate into organoids that mimic human physiological function.
The growth of the market for induced pluripotent stem cells was positively affected by the COVID-19 pandemic. Research and development activities for induced pluripotent stem cells (iPSCs) were expedited due to the increased emphasis on medical research and the pressing demand for innovative therapeutic treatments. Innovation and efficiency in the iPSCs production sector were boosted by a spike in investment and collaborative initiatives. Scientists used iPSC technology to study the virus, find new drugs, and create individualized therapies. The industry advanced due to the resurgence of interest in cell therapy and regenerative medicine.
Continuous developments in regenerative medicinal medications are a major market motivator in the worldwide pluripotent stem cell (iPSC) manufacturing industry. IPSCs, with to substantial investments in R&D, maintain tremendous potential for creating tailored and effective treatments for a wide range of medical conditions. By drawing investments from pharmaceutical firms and healthcare facilities, increasing the breadth of iPSC applications, and supplying fresh therapy possibilities, this improvement fuels market boom.
Ethical and regulatory concerns are a major obstacle in the global iPSC production industry. Some localities have implemented strict rules due to concerns about the use of chemicals derived from humans and the potential for abuse in the iPSC era. These obstacles can slow down research efforts, increase compliance fees, and cause market uncertainty, all of which affect how quickly iPSCs are adopted and commercialized.
The growing use of induced pluripotent stem cells (iPSCs) for disease modeling is a major trend in the worldwide iPSC production industry. With the goal of more accurate and personalized modeling of numerous diseases, including genetic disorders, neurological problems, and cardiovascular illnesses, researchers and pharmaceutical companies are utilizing iPSC technology to generate disorder-specific mobile traces. This movement is defining the future of precision medicine by facilitating drug development and improvement and opening the path for more targeted and effective healing strategies.
Report Coverage
Global Induced Pluripotent Stem Cells Production research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Induced Pluripotent Stem Cells Production report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Induced Pluripotent Stem Cells Production competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Induced Pluripotent Stem Cells Production market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Induced Pluripotent Stem Cells Production market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Induced Pluripotent Stem Cells Production market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Lonza, Axol Biosciences Ltd., Evotec SE, Hitachi Ltd., Merck KGaA, REPROCELLS, Inc., Fate Therapeutics, Thermo Fisher Scientific, Inc., StemCellsFactory III, Applied StemCells, Inc., Creative Biolabs, Bio-Techne Corporation.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2031. INFINITIVE DATA EXPERT has segmented the global Induced Pluripotent Stem Cells Production market based on the below-mentioned segments:
Global Induced Pluripotent Stem Cells Production Market, By Product
Products
Consumables & kits
Instruments/ devices
Automated platforms
Service
Global Induced Pluripotent Stem Cells Production market, By Application
Drug development & discovery
Regenerative medicine
Toxicology studies
Other applications
Global Induced Pluripotent Stem Cells Production Market, By End User
Pharmaceutical & biotechnology companies
Research & academic institutes
Contract research organizations
Global Induced Pluripotent Stem Cells Production market, Regional Analysis
With the advent of new regenerative medical drugs and mobile treatments, the worldwide market for induced pluripotent stem cell (iPSC) production has seen tremendous growth and innovation. An significant opportunity for the creation of individualized treatment plans and disease models exists in IPSCs, which can be reprogrammed from human cells into a pluripotent state.
An increasing body of knowledge on the potential applications of iPSCs in fields ranging from drug development to the treatment of various medical conditions is driving this market. Green induced pluripotent stem cell (iPSC) manufacturing that is both cost-effective and scalable is a hot topic among researchers and biotech companies. Innovations in this field are being propelled by partnerships between educational institutions, businesses, and healthcare facilities.
Furthermore, the need for standardized procedures and safety protocols is highlighted by the fact that strict regulatory frameworks and ethical concerns continue to play a significant role in defining the iPSC manufacturing landscape. With the ever-changing healthcare landscape on a global scale, the iPSC manufacturing market is set to continue growing, opening up new possibilities for medical discoveries and advancements in science.
The COVID-19 pandemic prompted a surge in research efforts, and within those efforts, iPSC-based studies saw a significant uptick. Researchers' incessant pursuit of better ways to control the spread of the SARS-CoV-2 virus has increased interest in induced pluripotent stem cells (iPSCs). Furthermore, the pathophysiology of human viral infection can be studied using generated pluripotent stem cells since these cells have the ability to differentiate into organoids that mimic human physiological function.
The growth of the market for induced pluripotent stem cells was positively affected by the COVID-19 pandemic. Research and development activities for induced pluripotent stem cells (iPSCs) were expedited due to the increased emphasis on medical research and the pressing demand for innovative therapeutic treatments. Innovation and efficiency in the iPSCs production sector were boosted by a spike in investment and collaborative initiatives. Scientists used iPSC technology to study the virus, find new drugs, and create individualized therapies. The industry advanced due to the resurgence of interest in cell therapy and regenerative medicine.
Continuous developments in regenerative medicinal medications are a major market motivator in the worldwide pluripotent stem cell (iPSC) manufacturing industry. IPSCs, with to substantial investments in R&D, maintain tremendous potential for creating tailored and effective treatments for a wide range of medical conditions. By drawing investments from pharmaceutical firms and healthcare facilities, increasing the breadth of iPSC applications, and supplying fresh therapy possibilities, this improvement fuels market boom.
Ethical and regulatory concerns are a major obstacle in the global iPSC production industry. Some localities have implemented strict rules due to concerns about the use of chemicals derived from humans and the potential for abuse in the iPSC era. These obstacles can slow down research efforts, increase compliance fees, and cause market uncertainty, all of which affect how quickly iPSCs are adopted and commercialized.
The growing use of induced pluripotent stem cells (iPSCs) for disease modeling is a major trend in the worldwide iPSC production industry. With the goal of more accurate and personalized modeling of numerous diseases, including genetic disorders, neurological problems, and cardiovascular illnesses, researchers and pharmaceutical companies are utilizing iPSC technology to generate disorder-specific mobile traces. This movement is defining the future of precision medicine by facilitating drug development and improvement and opening the path for more targeted and effective healing strategies.
Report Coverage
Global Induced Pluripotent Stem Cells Production research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Induced Pluripotent Stem Cells Production report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Induced Pluripotent Stem Cells Production competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Induced Pluripotent Stem Cells Production market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2031 |
| Base Year | 2024 |
| Forecast Period | 2024-2031 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Lonza, Axol Biosciences Ltd., Evotec SE, Hitachi Ltd., Merck KGaA, REPROCELLS, Inc., Fate Therapeutics, Thermo Fisher Scientific, Inc., StemCellsFactory III, Applied StemCells, Inc., Creative Biolabs, Bio-Techne Corporation. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Induced Pluripotent Stem Cells Production Market from 2021 to 2031.
- Market Forecast for Induced Pluripotent Stem Cells Production Market from 2021 to 2031.
- Regional Market Share and Revenue from 2021 to 2031.
- Country Market share within region from 2021 to 2031.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Induced Pluripotent Stem Cells Production competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Induced Pluripotent Stem Cells Production
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Induced Pluripotent Stem Cells Production market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Induced Pluripotent Stem Cells Production market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Lonza, Axol Biosciences Ltd., Evotec SE, Hitachi Ltd., Merck KGaA, REPROCELLS, Inc., Fate Therapeutics, Thermo Fisher Scientific, Inc., StemCellsFactory III, Applied StemCells, Inc., Creative Biolabs, Bio-Techne Corporation.
Primary Target Market
- Market Players of Induced Pluripotent Stem Cells Production
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2031. INFINITIVE DATA EXPERT has segmented the global Induced Pluripotent Stem Cells Production market based on the below-mentioned segments:
Global Induced Pluripotent Stem Cells Production Market, By Product
Products
Consumables & kits
Instruments/ devices
Automated platforms
Service
Global Induced Pluripotent Stem Cells Production market, By Application
Drug development & discovery
Regenerative medicine
Toxicology studies
Other applications
Global Induced Pluripotent Stem Cells Production Market, By End User
Pharmaceutical & biotechnology companies
Research & academic institutes
Contract research organizations
Global Induced Pluripotent Stem Cells Production market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive induced pluripotent stem cells production market market research and competitor analysis for your business to help you develop more profound insights into the induced pluripotent stem cells production market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the induced pluripotent stem cells production market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.